Literature DB >> 26765963

Monocarboxylate Transporters MCT1 and MCT4 Regulate Migration and Invasion of Pancreatic Ductal Adenocarcinoma Cells.

Su Chii Kong1, Asbjørn Nøhr-Nielsen, Katrine Zeeberg, Stephan Joel Reshkin, Else Kay Hoffmann, Ivana Novak, Stine Falsig Pedersen.   

Abstract

OBJECTIVES: Novel treatments for pancreatic ductal adenocarcinoma (PDAC) are severely needed. The aim of this work was to explore the roles of H-lactate monocarboxylate transporters 1 and 4 (MCT1 and MCT4) in PDAC cell migration and invasiveness.
METHODS: Monocarboxylate transporter expression, localization, activity, and function were explored in human PDAC cells (MIAPaCa-2, Panc-1, BxPC-3, AsPC-1) and normal human pancreatic ductal epithelial (HPDE) cells, by quantitative polymerase chain reaction, immunoblotting, immunocytochemistry, lactate flux, migration, and invasion assays.
RESULTS: MCT1 and MCT4 (messenger RNA, protein) were robustly expressed in all PDAC lines, localizing to the plasma membrane. Lactate influx capacity was highest in AsPC-1 cells and lowest in HPDE cells and was inhibited by the MCT inhibitor α-cyano-4-hydroxycinnamate (4-CIN), MCT1/MCT2 inhibitor AR-C155858, or knockdown of MCT1 or MCT4. PDAC cell migration was largely unaffected by MCT1/MCT2 inhibition or MCT1 knockdown but was reduced by 4-CIN and by MCT4 knockdown (BxPC-3). Invasion measured in Boyden chamber (BxPC-3, Panc-1) and spheroid outgrowth (BxPC-3) assays was attenuated by 4-CIN and AR-C155858 and by MCT1 or MCT4 knockdown.
CONCLUSIONS: Human PDAC cells exhibit robust MCT1 and MCT4 expression and partially MCT1- and MCT4-dependent lactate flux. PDAC cell migration is partially dependent on MCT4; and invasion, on MCT1 and MCT4. Inhibition of MCT1 and MCT4 may have clinical relevance in PDAC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26765963     DOI: 10.1097/MPA.0000000000000571

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  22 in total

Review 1.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model.

Authors:  Xiaowen Guan; Mark A Bryniarski; Marilyn E Morris
Journal:  AAPS J       Date:  2018-11-05       Impact factor: 4.009

3.  Development and validation of a liquid chromatography tandem mass spectrometry assay for AZD3965 in mouse plasma and tumor tissue: Application to pharmacokinetic and breast tumor xenograft studies.

Authors:  Xiaowen Guan; Donna Ruszaj; Marilyn E Morris
Journal:  J Pharm Biomed Anal       Date:  2018-03-31       Impact factor: 3.935

4.  CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion.

Authors:  Paweena Dana; Saowaluk Saisomboon; Ryusho Kariya; Seiji Okada; Sumalee Obchoei; Kanlayanee Sawanyawisuth; Chaisiri Wongkham; Chawalit Pairojkul; Sopit Wongkham; Kulthida Vaeteewoottacharn
Journal:  Cell Oncol (Dordr)       Date:  2019-11-15       Impact factor: 6.730

Review 5.  Transportome Malfunctions and the Hallmarks of Pancreatic Cancer.

Authors:  Qi Ling; Holger Kalthoff
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 6.  Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma.

Authors:  Abudureyimu Tuerhong; Jin Xu; Si Shi; Zhen Tan; Qingcai Meng; Jie Hua; Jiang Liu; Bo Zhang; Wei Wang; Xianjun Yu; Chen Liang
Journal:  Cell Mol Life Sci       Date:  2021-06-15       Impact factor: 9.261

Review 7.  Cancer cell metabolic plasticity in migration and metastasis.

Authors:  Jenna A Mosier; Samantha C Schwager; David A Boyajian; Cynthia A Reinhart-King
Journal:  Clin Exp Metastasis       Date:  2021-06-02       Impact factor: 5.150

8.  Cancer-associated fibroblasts enhance pancreatic cancer cell invasion by remodeling the metabolic conversion mechanism.

Authors:  Tao Shan; Shuo Chen; Xi Chen; Wan Run Lin; Wei Li; Jiancang Ma; Tao Wu; Xijuan Cui; Hong Ji; Yiming Li; Ya'an Kang
Journal:  Oncol Rep       Date:  2017-02-28       Impact factor: 3.906

9.  CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming.

Authors:  Agnieszka A Kendrick; Johnathon Schafer; Monika Dzieciatkowska; Travis Nemkov; Angelo D'Alessandro; Deepika Neelakantan; Heide L Ford; Chad G Pearson; Colin D Weekes; Kirk C Hansen; Elan Z Eisenmesser
Journal:  Oncotarget       Date:  2017-01-24

10.  MCT4 is induced by metastasis-enhancing pathogenic mitochondrial NADH dehydrogenase gene mutations and can be a therapeutic target.

Authors:  Keizo Takenaga; Nobuko Koshikawa; Miho Akimoto; Yasutoshi Tatsumi; Jason Lin; Makiko Itami; Hiroki Nagase
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.